Polaryx Therapeutics, Inc. has 1 Schedule 13D or 13G filing on record since 2026-02-05. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share ("common stock"). Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Mstone Partners Healthcare Limited | 48% | 22,452,954 | SCHEDULE 13D, 2026-02-05 | 2026-01-29 |
Purpose of Transaction (Item 4)
Mstone Partners Healthcare Limited
The Reporting Persons own 48.0% of the Company in the aggregate, based on 47,343,297 shares of Common Stock outstanding as of January 12, 2026. Mr. Yang serves as Chief Executive Officer and as a member of the board of directors of the Company (the "Board"), and, in such capacity, may have influence over the corporate activities of the Company, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management or the Board with respect to the business and affairs of the Company and may from time to time consider pursuing or proposing such matters with advisors, the Company or other persons.Item 4 of the SCHEDULE 13D filed 2026-02-05
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-05 | Mstone Partners Healthcare Limited | 48% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for Polaryx Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.